Compare Abeona Therapeutics Inc (ABEO) vs Campbell Soup Co. (CPB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Campbell Soup Co. — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Campbell Soup Co. trades at $22.09 (market cap $6.83B). The key difference: Campbell Soup Co. is far larger — about 18.3× Abeona Therapeutics Inc's market cap, and Campbell Soup Co. pays a 6.81% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | CPB | |
|---|---|---|
Market Cap | $373.32M | $6.83B |
Sector | Health | Consumer Staples |
52-Week High | $7.23 | $34.03 |
52-Week Low | $4.17 | $20.00 |
Enterprise Value | $228.22M | $13.44B |
Dividend Yield | — | 6.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Campbell's (CPB) trades at $22.90, down 1.8% today, with mixed technical signals showing bullish moving averages but neutral oscillators. The stock offers a 7% dividend yield but faces margin pressures with net income margin at 6.12%. Recent Q1 2026 earnings beat expectations at $0.50 EPS, though sales declined 4% year-over-year. The company is implementing cost cuts and portfolio simplification while expanding through partnerships like the new gluten-free soup with Banza.
CPB presents a value opportunity with low P/E of 11.11 and P/S of 0.68, but faces structural challenges including margin deterioration and competitive pressures. Analyst consensus leans cautious with 55% hold ratings and $19.75 price target below current levels. The high dividend yield provides income support, but investors should monitor execution of cost-saving initiatives and consumer response to new product innovations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →
